Healthcare Services

Myelodysplastic Syndrome Market Future Outlook Showing Expansion Toward $4.65 Billion by 2030

April 2, 2026April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Myelodysplastic Syndrome Market Evolve From 2026 To 2030?

The myelodysplastic syndrome market has shown substantial growth in recent years. It is anticipated to expand from $2.85 billion in 2025 to $3.12 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.8%. The expansion witnessed during the historical period is attributable to limited treatment options, an increasing occurrence of hematologic disorders, a higher rate of progression to AML, a reliance on supportive care, and difficulties in prompt diagnosis.

The myelodysplastic syndrome market size is projected to undergo rapid expansion in the coming years. It is expected to reach $4.65 billion by 2030, achieving a compound annual growth rate (CAGR) of 10.5%. The projected growth during this forecast period can be attributed to the advancement of targeted therapies, the wider availability of precision medicine solutions, increased funding for oncology research and development, progress in stem cell transplantation techniques, and the growing adoption of oral hypomethylating drugs. Key trends anticipated in the forecast period include the increasing acceptance of hypomethylating agents, the growing application of combination therapy approaches, a heightened emphasis on early detection and diagnostic accuracy, the expansion of stem cell transplantation and regenerative options, and a rising demand for supportive care and growth factor therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12920&type=smp

What Key Drivers Are Influencing The Growth Of The Myelodysplastic Syndrome Market?

The rising occurrence of rare blood cancers is projected to drive the expansion of the myelodysplastic syndrome (MDS) market moving ahead. These hematologic malignancies, characterized by a low population incidence, originate from cells within the bone marrow, lymph nodes, and other parts of the blood and immune system. Treatment for myelodysplastic syndrome (MDS) focuses on managing the condition, enhancing blood cell production, and alleviating related symptoms to halt the advancement of blood cancer in the bone marrow. As an illustration, data from the Leukemia and Lymphoma Society, a US-based professional organization, indicates that in September 2024, a diagnosis of leukemia, lymphoma, or myeloma occurs every 3 minutes for one person in the US. The year 2024 is projected to see 187,740 individuals diagnosed with these cancers, accounting for 9.4% of the anticipated 2,001,140 new cancer cases across the US. Consequently, the rising prevalence of blood cancer significantly propels the expansion of the myelodysplastic syndrome (MDS) market.

Which Segment Areas Are Covered In The Myelodysplastic Syndrome Market Analysis?

The myelodysplastic syndrome market covered in this report is segmented –

1) By Type: Myelodysplastic Syndrome With Unilineage Dysplasia, Myelodysplastic Syndrome With Multilineage Dysplasia, Myelodysplastic Syndrome With Ring Sideroblasts, Other Types

2) By Drug: Azacitidine, Lenalidomide, Decitabine, Deferasirox

3) By Treatment: Supportive Therapy, Growth Factors, Chemotherapy, Stem Cell Transplant, Other Treatments

4) By Route Of Administration: Oral, Injectable, Other Routes Of Administrations

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Myelodysplastic Syndrome With Unilineage Dysplasia: Type Of Dysplasia, Patient Demographics

2) By Myelodysplastic Syndrome With Multilineage Dysplasia: Severity Of Dysplasia, Patient Demographics

3) By Myelodysplastic Syndrome With Ring Sideroblasts: Percentage Of Ring Sideroblasts, Treatment Options

4) By Other Types: Specific Types, Treatment Options

What Major Market Trends Are Driving Changes In The Myelodysplastic Syndrome Market?

Major companies operating in the myelodysplastic syndrome (MDS) market are dedicating efforts to creating innovative advancements, specifically first-line erythroid maturation therapies, to enhance anemia management and lessen the dependence on frequent red blood cell transfusions. These first-line erythroid maturation therapies are defined as targeted treatments that boost late-stage red blood cell development, enabling a quicker and more lasting correction of anemia in patients who have not yet been treated with erythropoiesis-stimulating agents. For instance, in August 2023, Bristol Myers Squibb, a pharmaceutical industry company from the US, obtained FDA approval for Reblozyl (luspatercept-aamt) as a primary treatment for anemia in ESA-naïve adults with low- to intermediate-risk myelodysplastic syndromes (MDS) who might need regular red blood cell transfusions. The Phase 3 COMMANDS trial showed that Reblozyl had superior effectiveness in achieving red blood cell transfusion independence and increasing hemoglobin levels compared to epoetin alfa, thereby addressing anemia sooner in a wider population of patients.

Which Global Companies Are Actively Competing In The Myelodysplastic Syndrome Market?

Major companies operating in the myelodysplastic syndrome market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Jazz Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Lupin Limited, BeiGene, Janssen Biotech, Accord Healthcare, Acceleron Pharma Inc.

Read the full myelodysplastic syndrome market report here:

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Myelodysplastic Syndrome Market?

North America was the largest region in the myelodysplastic syndrome market in 2025. The regions covered in the myelodysplastic syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Myelodysplastic Syndrome Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12920&type=smp

Browse Through More Reports Similar to the Global Myelodysplastic Syndrome Market 2026, By The Business Research Company

Histoplasmosis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/histoplasmosis-treatment-global-market-report

Onychomycosis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report

Vitiligo Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/vitiligo-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795